
Claims

1. Use of a compound represented by formula III below in the manufacture of a medicament for the treatment of cancer,



(Ⅲ)

(where n is an integer of 200 to 1,000)

wherein the medicament is to be parenterally administered to a patient at a single dose of 0.01 μmol compound/kg body weight to 11 μmol compound/kg body weight and at a frequency of once a week for a period of at least 2 weeks, thereby having no irinotecan-like side effect that comprises myelosuppression and providing a cancer growth inhibiting activity equivalent to or larger than Irinotecan, when the medicament is administered at a dose of 1/10 or less in the molar ratio of compound to irinotecan.

2. The use according to claim 1, wherein in the formula III, n is an integer of 200 to 800.

3. The use according to claim 1 or 2, wherein the cancer is selected from the group consisting of colon cancer, breast cancer, ovarian cancer, cervical cancer, uterine cancer, lung cancer, stomach cancer, pancreas cancer, esophageal cancer, head and neck cancer, hepatocellular carcinoma, gallbladder cancer, biliary cancer, sarcoma, and malignant lymphoma.

4. The use according to any one of claims 1 to 3, wherein the medicament is intravenously administered.

5. The use according to claim 4, wherein the administration is infusion or bolus injection.